Effectiveness of Convalescent Immune Plasma Therapy

Not Applicable

Completed

• Conditions: Acute Respiratory Distress Syndrome

• Registration Number: NCT04442958
• Lead Sponsor: Bagcilar Training and Research Hospital

Brief Summary

The aim of the study is to evaluate the safety, improvement of clinical symptoms and laboratory parameters of convalescent immune plasma treatment in severe Covid-19 patients with ARDS.

Detailed Description

The aim of the study is to evaluate the safety, improvement of clinical symptoms with hypoxemia, metabolic and laboratory parameters of patients with convalescent immune plasma treatment in severe Covid-19 patients followed up in critical care unit.

Study Timeline

• Study Start: 2020-05-15
• Status Verified: 2020-06
• Primary Completion: 2020-06-15
• Study Completion: 2020-06-17
• Study First Submitted: 2020-06-17
• Study First Submitted QC: 2020-06-19
• Study First Posted: 2020-06-23
• Last Update Submitted: 2020-06-30
• Last Update Posted: 2020-07-01

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Primary Outcome Measures

Name	Time	Method
Plasma procalcitonin level	7. day	Infection markers
D-Dimer level	7. day	Hypercoagulability
C-Reactive protein level	7. day	Infection markers
Lymphocyte count	7. day	Infection markers
Plasma fibrinogen level	7. day	Coagulopathy
Plasma ferritin level	7. day	Acute phase reactant

Secondary Outcome Measures

Name	Time	Method
Arterial Oxygen level	7. day	Arterial oxygenation
Partial Oxygen Saturation level	7. day	Arterial oxygenation
Fractional Inspired Oxygen Level	7. day	Arterial oxygenation

Trial Locations

Locations (1)

Istanbul Bagcılar Training and Research Hospital; 🇹🇷 Istanbul, Turkey